http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results
-
GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
-
GBT Announces New Employment Inducement Grants
-
GBT Commits $250,000 to Support the Sickle Cell Disease Community During COVID-19 Pandemic
-
GBT Takes Steps to Support Public Health Efforts to Address COVID-19 Pandemic
-
GBT Announces New Employment Inducement Grants
-
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2019 Financial Results
-
GBT Announces Participation at the Cowen and Company 40th Annual Healthcare Conference
-
GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease
-
GBT to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
-
GBT Announces New Employment Inducement Grants
-
GBT Announces New Employment Inducement Grants
-
GBT Announces New Employment Inducement Grants
-
GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference
-
Global Blood Therapeutics (GBT) Secures $150 Million Non-Dilutive Term Loan Financing
-
GBT Secures $150 Million Non-Dilutive Term Loan Financing
-
Global Blood Therapeutics (GBT) and Syros Partner (SYRS) to Discover, Develop and Commercialize Novel Therapies for SCD and Beta Thalassemia
-
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at Upcoming Investor Conferences in December
-
Global Blood Therapeutics (GBT) Confirms FDA Approves Oxbryta for SCD
-
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
-
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
-
GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results
-
Global Blood Therapeutics (GBT) Announces Upcoming Data Presentations at ASH
-
GBT Announces Upcoming Data Presentations at 61st American Society of Hematology Annual Meeting & Exposition
-
GBT Announces New Employment Inducement Grants
-
GBT (GBT) Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with SCD Treated with Voxelotor
-
GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention
-
GBT to Host Analyst & Investor Day on October 8 in New York
-
GBT Announces Participation at the 2019 Cantor Global Healthcare Conference
-
Global Blood Therapeutics (GBT) Announces FDA Acceptance of NDA and Priority Review for Voxelotor for Treatment of SCD
-
GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference
-
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
-
GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results
-
GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference
-
GBT Announces New Employment Inducement Grants
-
GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants
-
GBT (GBT) Announces Updated 24-Week Efficacy Data from Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
-
GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
-
GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
-
GBT Reports Recent Business Progress and First Quarter 2019 Financial Results
-
GBT Announces New Employment Inducement Grants

